흉부 대동맥류 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 제품별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Thoracic Aortic Aneurysm Market Summary

The global thoracic aortic aneurysm market size was estimated at USD 1.65 billion in 2024 and is projected to reach USD 5.04 billion by 2033, growing at a CAGR of 13.36% from 2025 to 2033. This growth is driven by the rising prevalence of hypertension and connective tissue disorders, an increasing aging population, and growing adoption of minimally invasive endovascular procedures.

Technological advancements in stent graft design, improved diagnostic imaging, and early disease detection contribute to market expansion. Supportive reimbursement policies and expanding awareness of thoracic aortic aneurysms among both physicians and patients are further accelerating treatment uptake globally.

The increasing prevalence of hypertension, smoking, and atherosclerosis, which are key risk factors for thoracic aortic aneurysm, is a major driver of market growth. As aging populations grow globally, the incidence of degenerative vascular conditions continues to rise, directly increasing the demand for diagnostic and therapeutic solutions. In March 2025, an article published in Biomedicines analyzed the relationship between atherosclerosis (AS) and aortic aneurysm (AA), including thoracic AA (TAA). It reported comorbidity rates ranging from 18% to 90%, influenced by aneurysm location, age, genetic background, and bicuspid aortic valves.

Technological advancements in endovascular aneurysm repair (TEVAR) have significantly boosted the market by offering minimally invasive alternatives to open surgery. These innovations have led to reduced hospital stays, lower procedural risks, and expanded treatment eligibility for high-risk patients. Device manufacturers are continually developing next-generation stent grafts with enhanced precision, flexibility, and durability, further accelerating their adoption among vascular surgeons worldwide. In May 2025, SHIP International Hospital in Dhaka performed a Thoracic Endovascular Aortic Repair (TEVAR) on a 57-year-old patient with a thoracic aortic aneurysm (TAA), a bulge in the chest portion of the aorta. Referred by a NICVD professor after being denied treatment elsewhere, the patient underwent the minimally invasive procedure with support from an endovascular stent graft vendor.

The growing use of advanced imaging modalities such as CT angiography, MRI, and ultrasound for early and accurate detection of thoracic aortic aneurysms is fueling market growth. National screening programs and increased awareness among both clinicians and patients are contributing to earlier diagnosis and timely intervention. In parallel, artificial intelligence tools and digital health platforms are being integrated into diagnostic pathways, supporting better risk stratification and patient monitoring.

In June 2025, an article published in Nature Communications discussed an AI model that enables opportunistic screening for thoracic aortic aneurysms (TAA) using routine breast MRI scans. The model improved detection rates by 3.5X compared to standard clinical reads. It flagged high-risk patients based on both aortic size and body-size-adjusted indices like AHI and ASI.

Global Thoracic Aortic Aneurysm Market Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global thoracic aortic aneurysm market report based on treatment, product, end use, and region:

• Treatment Outlook (Revenue USD Million, 2021 - 2033)
• Open Surgical Repair (OSR)
• Thoracic Endovascular Aneurysm Repair (TEVAR)
• Branched Endovascular Aneurysm Repair (BEVAR)
• Hybrid Procedures
• Product Outlook (Revenue USD Million, 2021 - 2033)
• Aortic Stent Grafts
• Aortic Surgical Grafts
• Aortic Repair Accessory Devices
• End Use Outlook (Revenue USD Million, 2021 - 2033)
• Hospitals
• Ambulatory Surgery Centers (ASC)
• Clinics
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment outlook
  • 2.2.2. Product outlook
  • 2.2.3. End use outlook
• 2.3. Competitive Insights

Chapter 3. Global Thoracic Aortic Aneurysm Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Global Thoracic Aortic Aneurysm: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis
• 3.4. Treatment Landscape
• 3.5. Case Study Analysis

Chapter 4. Global Thoracic Aortic Aneurysm Market Segment Analysis, By Treatment, 2021-2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Treatment Market Share Analysis, 2024 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Thoracic Aortic Aneurysm Market, by Treatment, 2021 to 2033
• 4.5. Open Surgical Repair (OSR)
  • 4.5.1. Open surgical repair (OSR) market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.6. Thoracic Endovascular Aneurysm Repair (TEVAR)
  • 4.6.1. Thoracic endovascular aneurysm repair (TEVAR) market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.7. Hybrid Procedures
  • 4.7.1. Hybrid procedures market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.8. Branched Endovascular Aneurysm Repair (BEVAR)
  • 4.8.1. Branched endovascular aneurysm repair (BEVAR) market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Global Thoracic Aortic Aneurysm Market Segment Analysis, By Product, 2021-2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. Product Market Share Analysis, 2024 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Thoracic Aortic Aneurysm Market, by Product, 2021 to 2033
• 5.5. Aortic Stent Grafts
  • 5.5.1. Aortic stent grafts market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.6. Aortic Surgical Grafts
  • 5.6.1. Aortic surgical grafts market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.7. Aortic Repair Accessory Devices
  • 5.7.1. Aortic repair accessory devices market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Global Thoracic Aortic Aneurysm Market Segment Analysis, By End Use, 2021-2033 (USD Million)

• 6.1. Definition and Scope
• 6.2. End Use Market Share Analysis, 2024 & 2033
• 6.3. Segment Dashboard
• 6.4. Global Thoracic Aortic Aneurysm Market, by End Use, 2021 to 2033
• 6.5. Hospitals
  • 6.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.6. Ambulatory surgery centers (ASC)
  • 6.6.1. Ambulatory surgery centers (ASC) market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.7. Clinics
  • 6.7.1. Clinics market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Thoracic Aortic Aneurysm Market Segment Analysis, By Region, 2021- 2033 (USD Million)

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Regional Market Snapshot
• 7.4. Thoracic Aortic Aneurysm Market Share by Region, 2024 & 2033:
• 7.5. North America
  • 7.5.1. North America thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Scenario
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. U.S. thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Scenario
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Canada thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Scenario
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Mexico thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Scenario
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. UK thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Scenario
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Germany thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Scenario
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. France thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Scenario
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Italy thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Scenario
    • 7.6.6.3. Competitive Scenario
    • 7.6.6.4. Spain thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.6.7. Norway
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Scenario
    • 7.6.7.3. Competitive Scenario
    • 7.6.7.4. Norway thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Regulatory Scenario
    • 7.6.8.3. Competitive Scenario
    • 7.6.8.4. Sweden thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.6.9. Denmark
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Regulatory Scenario
    • 7.6.9.3. Competitive Scenario
    • 7.6.9.4. Denmark thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Regulatory Scenario
    • 7.7.1.3. Competitive Scenario
    • 7.7.1.4. Japan thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Scenario
    • 7.7.2.3. Competitive Scenario
    • 7.7.2.4. China thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Scenario
    • 7.7.3.3. Competitive Scenario
    • 7.7.3.4. India thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Regulatory Scenario
    • 7.7.4.3. Competitive Scenario
    • 7.7.4.4. Australia thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Regulatory Scenario
    • 7.7.5.3. Competitive Scenario
    • 7.7.5.4. South Korea thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Regulatory Scenario
    • 7.7.6.3. Competitive Scenario
    • 7.7.6.4. Thailand thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Regulatory Scenario
    • 7.8.1.3. Competitive Scenario
    • 7.8.1.4. Brazil thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Scenario
    • 7.8.2.3. Competitive Scenario
    • 7.8.2.4. Argentina thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key Country Dynamics
    • 7.9.1.2. Regulatory Scenario
    • 7.9.1.3. Competitive Scenario
    • 7.9.1.4. South Africa thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Regulatory Scenario
    • 7.9.2.3. Competitive Scenario
    • 7.9.2.4. Saudi Arabia thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Regulatory Scenario
    • 7.9.3.3. Competitive Scenario
    • 7.9.3.4. UAE thoracic aortic aneurysm market, 2021 - 2033 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Regulatory Scenario
    • 7.9.4.3. Competitive Scenario
    • 7.9.4.4. Kuwait thoracic aortic aneurysm market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Profiles
  • 8.3.1. Medtronic plc
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. W.L. Gore & Associates, Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Cook Medical Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Terumo Corporation
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. MicroPort Scientific Corporation
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Boston Scientific Corporation
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Artivion Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Cardiatis S.A.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Endologix Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Braile Biomedica
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Lombard Medical
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. CryoLife, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives